key: cord-0870316-qwylkkbt authors: Martínez-Baz, Iván; Miqueleiz, Ana; Casado, Itziar; Navascués, Ana; Trobajo-Sanmartín, Camino; Burgui, Cristina; Guevara, Marcela; Ezpeleta, Carmen; Castilla, Jesús; Ibero Esparza, Carlos; Herranz, Mercedes; Arregui, Irati; Martín, Carmen; Miqueleiz, Ana; Navascués, Ana; Polo, Isabel; Trobajo-Sanmartín, Camino; Ezpeleta, Carmen; Estévez, Ingrid; Tordoya, Igberto; Quílez, Delia; Lameiro, Francisco; Álvaro, Ana Isabel; López Moreno, Paula; Albéniz, Esther; Elía, Fernando; Gorricho, Javier; Ardanaz, Eva; Ascunce, Nieves; Arriazu, Maite; Baigorria, Fernando; Barricarte, Aurelio; Burgui, Cristina; Casado, Itziar; de la Cruz, Enrique; Díaz, Jorge; Ederra, María; Egüés, Nerea; García Cenoz, Manuel; Guevara, Marcela; Iriarte, Nerea; Martínez-Baz, Iván; Moreno-Iribas, Conchi; Sayón, Carmen; Vidán, Juana; Nuín, Marian; Castilla, Jesús title: Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021 date: 2021-05-27 journal: Euro Surveill DOI: 10.2807/1560-7917.es.2021.26.21.2100438 sha: 73ceb09c64e6cc943eec7d1f2d8667b19befe1d9 doc_id: 870316 cord_uid: qwylkkbt COVID-19 vaccine effectiveness was evaluated in close contacts of cases diagnosed during January–April 2021. Among 20,961 contacts, 7,240 SARS-CoV-2 infections were confirmed, with 5,467 being symptomatic and 559 leading to hospitalisations. Non-brand-specific one and two dose vaccine effectiveness were respectively, 35% (95% confidence interval (CI): 25 to 44) and 66% (95% CI: 57 to 74) against infections, 42% (95% CI: 31 to 52) and 82% (95% CI: 74 to 88) against symptomatic infection, and 72% (95% CI: 47 to 85) and 95% (95% CI: 62 to 99) against COVID-19 hospitalisation. The second dose significantly increased effectiveness. Findings support continuing complete vaccination. COVID-19 vaccine effectiveness was evaluated in close contacts of cases diagnosed during January-April 2021. Among 20,961 contacts, 7,240 SARS-CoV-2 infections were confirmed, with 5,467 being symptomatic and 559 leading to hospitalisations. Non-brand-specific one and two dose vaccine effectiveness were respectively, 35% (95% confidence interval (CI): 25 to 44) and 66% (95% CI: 57 to 74) against infections, 42% (95% CI: 31 to 52) and 82% (95% CI: 74 to 88) against symptomatic infection, and 72% (95% CI: 47 to 85) and 95% (95% CI: 62 to 99) against COVID-19 hospitalisation. The second dose significantly increased effectiveness. Findings support continuing complete vaccination. In this study in Navarre, Spain, we estimate the effectiveness of coronavirus disease (COVID-19) vaccines in preventing confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, symptomatic confirmed SARS-CoV-2 infections and COVID-19 hospitalisations in adults (≥ 18 years old) who had had close contact to a person with confirmed SARS-CoV-2 infection. This prospective cohort study included all individuals aged ≥ 18 years covered by the Navarre Health Service, who had been close contacts of laboratory-confirmed COVID-19 cases from January to April 2021. As part of measures to control COVID-19, all laboratoryconfirmed COVID-19 cases, according to the European Union definition [1] , were interviewed to identify their close contacts [2] . A close contact of a COVID-19 case was defined as any person who had had high-risk exposure to a confirmed COVID-19 case within a timeframe ranging from 2 days before the onset of symptoms in the case to 10 days after the onset of symptoms, or in the 2 days before the sample, which led to confirmation was taken, to 10 days after the sample was taken for asymptomatic cases [3] . Close contacts were tested by reverse-transcription (RT)-PCR for SARS-CoV-2 in nasopharynx samples initially and 10 days after the last contact. In symptomatic contacts, a positive antigen test within 5 days from the symptom onset was also considered confirmatory of SARS-CoV-2 infection, because these tests have demonstrated very high specificity [4, 5] . Close contacts with a positive test for SARS-CoV-2 before January 2021, nursing home residents and those who did not complete the testing protocol were excluded from the study. COVID-19 hospitalisation entailed admission due to laboratory-confirmed COVID-19 for ≥ 24 hours. Age, sex, chronic conditions, healthcare work and contact setting (household or other) were obtained from the enhanced epidemiological surveillance of COVID-19 [2] . progressive incorporation of Moderna and Vaxzevria vaccines. Vaccination was successively targeted to residents and workers in long-term care facilities, healthcare workers, people with disabilities, individuals aged ≥ 80 years, essential workers, persons with highrisk conditions, and individuals in the general population aged ≥ 60 years [9] . COVID-19 vaccine doses, brand and date of administration were obtained from the regional vaccination register. Each dose was considered potentially effective 14 days after administration [10]. The incidences of SARS-CoV-2 infection, symptomatic COVID-19 and hospitalisation were compared by COVID-19 vaccination status. The same risk period was assigned to everyone in the cohort; therefore, the Cox regression provided estimates of the crude and adjusted relative risks (RR) with 95% confidence intervals (CI) [11] . Adjusted models included age groups, sex, major chronic condition, contact setting (household or other) and month. Contacts who had received the first dose < 14 days before testing were excluded from the analyses. Vaccine effectiveness (VE) was estimated as a percentage: (1 − adjusted RR) × 100. Interaction between vaccination status and age group was tested. The relative effectiveness of two doses vs one dose was also evaluated. Sensitivity analyses in household contacts or considering only RT-PCR results were performed. This study was approved by the Ethical Committee for Clinical Research in Navarre (PI2020/45), which waived the requirement of obtaining informed consent. The cohort included 20,961 close contacts, 7,240 (34.5%) were confirmed as infected with SARS-CoV-2, with 5,467 (26.1%) having symptomatic infections, and 559 (2.7%) needing hospitalisation for COVID-19. Among the close contacts, 50.4% were household contacts, 78.3% were < 60 years old, 6.5% (n = 1,381) had received any dose of a vaccine and 2.4% (n = 512) had received the second dose ≥ 14 days before testing (Figure and Table 1 ). The incidence of SARS-CoV-2 infection was higher in unvaccinated contacts (35.6%) than in those vaccinated with one or two doses (22.8% and 12.1%, respectively). Incidence of symptomatic COVID-19 was 27.1% in unvaccinated contacts and declined in those vaccinated with one (15.5%) and two doses (5.1%). (Table 1) . COVID-19 VE of one and two doses were, respectively, 35% (95% CI: 25 to 44) and 66% (95% CI: 57 to 74) against SARS-CoV-2 infections. VE estimates improved against symptomatic COVID-19 (42%; 95% CI: 31 to 52, and 82%; 95% CI: 74 to 88, respectively), and were even higher against hospitalised cases (72%; 95% CI: 47 to 85, and 95%; 95% CI: 62 to 99). Among people vaccinated with one dose, the second dose increased significantly the VE in preventing SARS-CoV-2 infection (relative effect 48%; 95% CI: 31 to 61) and symptomatic COVID-19 (relative effect 69%; 95% CI: 53 to 80) ( Table 2 ). The VE against symptomatic COVID-19 was higher in people aged 18-59 years than in those aged ≥ 60 years for one dose (51%; 95% CI: 37 to 62, vs 30%; 95% CI: 10 to 45, p interaction = 0.065) and two doses (84%; 95% CI: 74 to 90, vs 77%; 95% CI: 56 to 88, p interaction = 0.375), although these differences were not statistically significant ( Table 2 ). The relative effect of two doses vs one was similar in both age groups. Sensitivity analyses limited to household contacts or considering only RT-PCR results showed similar estimates (Supplementary Tables S1 and S2 ). In people aged 18-59 years, the effectiveness of Comirnaty against symptomatic COVID-19 was 50% (95% CI: 12 to 72) for one dose and 85% (95% CI: 74 to 91) for two doses, while in people aged ≥ 60 years the estimates were 20% (95% CI:−7 to 40) and 76% (95% CI: 55 to 87), respectively ( (Table 3 ). By 2 May 2021, the COVID-19 pandemic has caused over 3.5 million cases and 78,000 deaths in Spain [12] . some recent observational studies [13] [14] [15] [16] [17] [18] [19] . These differences could be explained because some studies may not represent the general population (e.g. studies in healthcare workers), include an indirect effect in highly vaccinated groups, consider a short follow-up, or might be affected by residual bias due to lower risk exposure of vaccinated subjects. Our results highlight several aspects with relevant practical implications. The VE of Comirnaty seemed to be lower in older people than in young adults. As the risk of vaccine failures increases with age, additional preventive measures should be maintained and community immunity should be guaranteed around vulnerable persons. The effectiveness of one dose of Vaxzevria was moderate in preventing infection in adults aged < 70 years in < 4 months after administration. In our study, complete vaccination with Comirnaty demonstrated very high effectiveness in preventing COVID-19 hospitalisation, which may have a very positive impact on the healthcare system. However, as the VE in preventing confirmed infection was moderate, the study and quarantine of complete vaccinated individuals when they are close contacts of confirmed cases may remain recommendable, since the possibility of acquiring and transmitting the infection has not been totally excluded. Compared with the test-negative and specific-cohort designs, the cohort of close contacts has advantages for bias control, since participants had a similar risk exposure regardless their vaccination status, and provided a good representativeness of the general population [20] . Only close contacts tested for COVID-19 were included in this study. This study has some limitations. The proportion of vaccinated persons was low and results are preliminary. As no contact had received two doses of Vaxzevria, this effectiveness could not be estimated. The study included individuals with different chance for vaccination, but age, comorbidity and month were included 40 -59 and ≥ 60 years), sex, contact setting (household or other), major chronic conditions and month. e Asymptomatic and symptomatic COVID-19 infections. f Interaction between age group and vaccination with one dose of Vaxzevria (p = 0.809), vaccination with one dose of Comirnaty (p = 0.179) and vaccination with two doses of Comirnaty (p = 0.327). Comparison of brands should be avoided from this study since they were not randomly distributed. in the analysis. Symptomatic patients with positive antigen test were included; however, the sensitivity analysis including only RT-PCR results provided similar estimates. Some close contacts who had received the first dose < 14 days before testing could have been unnecessarily excluded. Comparison of brands should be avoided from this study since they were not randomly distributed. VE estimates were obtained under specific epidemiological and vaccination conditions and may vary in other populations and moments. COVID-19 VE was moderate in preventing SARS-CoV-2 infection and was higher against symptomatic and hospitalised cases. One dose of COVID-19 vaccine showed a moderate effect and two doses reached a high effectiveness in reducing symptomatic COVID-19 and hospitalisation. The second dose significantly improved the effectiveness. These findings highlight the benefit of immunization against SARS-CoV-2 and support continuing to complete vaccination. Case definition for coronavirus disease 2019 (COVID-19, as of 3 Estrategia de detección precoz, vigilancia y control de COVID-19. Actualizado a 26 de febrero de 2021. [Strategy for early detection, surveillance and control of COVID-19 Contact tracing: public health management of persons, including healthcare workers, who have had contact with COVID-19 cases in the European Union -third update Stockholm: ECDC; 2020 Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine World Health Organization (WHO). Evaluation of COVID-19 vaccine effectiveness. Interim Guidance Methods for estimating relative risk in studies of common binary outcomes WHO coronavirus (COVID-19) dashboard. Geneva: WHO Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers -Eight U.S. locations Effectiveness of Pfizer-BioNTech and Moderna Vaccines against COVID-19 among hospitalized adults aged ≥65 years -United States Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province Theoretical framework for retrospective studies of the effectiveness of SARS-CoV-2 vaccines License, supplementary material and copyright Funding statement: This study was supported by the Horizon 2020 program of the European Commission (I-MOVE-COVID-19, grant agreement No 101003673), and by the Carlos III Institute of Health with the European Regional Development Fund (COV20/00542).